Literature DB >> 11812771

KEPI, a PKC-dependent protein phosphatase 1 inhibitor regulated by morphine.

Qing-Rong Liu1, Ping-Wu Zhang, Qiaoxi Zhen, Donna Walther, Xiao-Bing Wang, George R Uhl.   

Abstract

cDNAs encoding KEPI, a novel protein kinase C (PKC)-potentiated inhibitory protein for type 1 Ser/Thr protein phosphatase (PP1), were identified. They were found among morphine-regulated brain mRNAs identified using subtracted differential display techniques. Full-length rat, mouse, and human cDNA and genomic sequences were elucidated with library screening and data base searching. Rat, mouse, and human KEPI cDNAs encode 164-165 amino acid proteins with calculated isoelectric points of 5.2. Each species' amino acid sequence contains consensus sequences for phosphorylation by PKC (KVT(72)VK), protein kinase A (RKLS(154)), and casein kinase II (S(43)SRE, S(120)EEE). Multiple KEPI N-terminal myristoylation consensus sites provide potential regions for membrane anchoring. Subcellular fractionation and Western analyses revealed that most KEPI immunoreactivity was associated with P2 and P3 membrane-enriched fractions and little in cytosolic fractions. 2.6-kb KEPI mRNAs were detected in brain, especially in the cerebral cortex and hippocampus, and in heart and skeletal muscle. Brain KEPI mRNA was up-regulated by both acute and chronic morphine treatments. The human KEPI gene contains four exons extending over more than 100 kb of genomic sequence on 6q24-q25, near the mu opiate receptor gene. These sequences displayed sufficient homology with the porcine PP1 inhibitor CPI-17 that we asked whether KEPI could share the ability of CPI-17 to modulate PP1 activity in a PKC-dependent fashion. Recombinant mouse KEPI is phosphorylated by PKC with a K(m) of 2.6 microm and a t(1/2) of 20 min. Phospho-KEPI inhibits PP1alpha with an IC(50) of 2.7 nm, a potency more than 600-fold greater than that displayed by unphosphorylated KEPI. Neither phospho- nor dephospho-KEPI inhibits protein phosphatase 2A. Up-regulation of KEPI expression by morphine, an agonist at PKC-regulating G-protein-coupled mu receptors, provides a novel signaling paradigm in which the half-lives of serine/threonine phosphorylation events can be influenced by activities at G(i)/G(o)-coupled receptors that modulate KEPI expression, KEPI phosphorylation, and KEPI regulation of PP1 activity.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11812771     DOI: 10.1074/jbc.M107558200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  22 in total

1.  Expression profiling to understand actions of NMDA/glutamate receptor antagonists in rat brain.

Authors:  Petri Törönen; Marcus Storvik; Anni-Maija Lindén; Outi Kontkane; Markéta Marvanová; Merja Lakso; Eero Castrén; Garry Wong
Journal:  Neurochem Res       Date:  2002-10       Impact factor: 3.996

Review 2.  Endogenous inhibitor proteins that connect Ser/Thr kinases and phosphatases in cell signaling.

Authors:  Masumi Eto; David L Brautigan
Journal:  IUBMB Life       Date:  2012-07-20       Impact factor: 3.885

3.  A bioinformatic and computational study of myosin phosphatase subunit diversity.

Authors:  Rachael P Dippold; Steven A Fisher
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2014-06-04       Impact factor: 3.619

4.  GBPI, a novel gastrointestinal- and brain-specific PP1-inhibitory protein, is activated by PKC and inactivated by PKA.

Authors:  Qing-Rong Liu; Ping-Wu Zhang; Zhicheng Lin; Qi-Fu Li; Amina S Woods; Juan Troncoso; George R Uhl
Journal:  Biochem J       Date:  2004-01-01       Impact factor: 3.857

5.  Contractile agonists attenuate cGMP levels by stimulating phosphorylation of cGMP-specific PDE5; an effect mediated by RhoA/PKC-dependent inhibition of protein phosphatase 1.

Authors:  K S Murthy
Journal:  Br J Pharmacol       Date:  2008-01-21       Impact factor: 8.739

6.  Novel mutation in TP63 associated with ectrodactyly ectodermal dysplasia and clefting syndrome and T cell lymphopenia.

Authors:  Philip F Giampietro; Mei W Baker; Monica J Basehore; Julie R Jones; Christine M Seroogy
Journal:  Am J Med Genet A       Date:  2013-04-23       Impact factor: 2.802

7.  Analysis of candidate genes for morphine preference quantitative trait locus Mop2.

Authors:  G A Doyle; C L Schwebel; S E Ruiz; A D Chou; A T Lai; M-J Wang; G G Smith; R J Buono; W H Berrettini; T N Ferraro
Journal:  Neuroscience       Date:  2014-07-22       Impact factor: 3.590

Review 8.  Regulation of cellular protein phosphatase-1 (PP1) by phosphorylation of the CPI-17 family, C-kinase-activated PP1 inhibitors.

Authors:  Masumi Eto
Journal:  J Biol Chem       Date:  2009-12-18       Impact factor: 5.157

9.  Effect of KEPI (Ppp1r14c) deletion on morphine analgesia and tolerance in mice of different genetic backgrounds: when a knockout is near a relevant quantitative trait locus.

Authors:  J Drgonova; D B Zimonjic; F S Hall; G R Uhl
Journal:  Neuroscience       Date:  2009-10-09       Impact factor: 3.590

10.  Phosphoprotein inhibitor CPI-17 specificity depends on allosteric regulation of protein phosphatase-1 by regulatory subunits.

Authors:  Masumi Eto; Toshio Kitazawa; David L Brautigan
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-07       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.